

97
Claim 15. (Amended) A method of [vaccinating] reducing the toxicity of a normally toxic biologically active factor in a vaccine for a human or animal [against] disease comprising the step of administering to the human or animal a composition comprising an immunologically effective amount of an admixture of a colloidal metal and a toxic biologically active factor such that the composition elicits an immunological response to the biologically-active factor, and reduces toxic side effects resulting from the biologically active factor, while retaining the biological activity of the normally toxic biologically-active factor.


A3
Claim 19. (Amended) A method of [treating] reducing the toxicity of a normally toxic biologically active factor in a therapeutic composition for a human or animal with a cancer or immune disease comprising the step of administering to the human or animal with the cancer or immune disease a therapeutically effective amount of a composition comprising an admixture of a colloidal metal and a toxic biologically-active factor such that the composition elicits an immunological response to the biologically-active factor, and reduces toxic side effects resulting from the biologically active factor, while retaining the biological activity of the toxic biologically-active factor.

REMARKS

Consideration of the present application in light of the foregoing amended claims and the following remarks is respectfully requested. Upon entry of the foregoing amendments, there will be 15 claims pending. The pending claims are directed to a method of reducing the toxicity of a normally toxic biologically-active factor in humans and animals while retaining its biological activity. The claims, as amended, more particularly point out the inventive aspects of the invention over the prior art. Support for the amendments to Claims 8, 15, and 19, is found in the specification at page 1, lines 26-30; page 3, lines 18-26, and lines 34- page 4, line 1; page 4, lines 18-20; page 5, lines 29- page 6, line 1; page 6, lines 7-15; page 9, lines 7-16; and page 14, lines 19-20, and lines 34-35. Applicants intend to pursue the composition claims, Claims 1-7, in a continuation application.

Respectfully submitted,

JONES & ASKEW


By: James Dean Johnson, Ph.D.

37th Floor
191 Peachtree Street, N.E.
Atlanta, Georgia 30303-1769
(404) 818-3700
Our File: 01994-0021